子供はどのくらいの頻度で咳をするのか?

Same author

Corrigendum to "Critical Care Outcome Prediction Equation (COPE) model, version 7" [Crit Care Resusc 27 (4) (2025) 100131].

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine·2026

Same author

ANZROD, COPE 4 and PIM 3: caveat emptor.

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine·2014

Same author

Heterologous ("nonspecific") and sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2013

Same author

Validation of the hospital outcome prediction equation (HOPE) model for monitoring clinical performance.

Internal medicine journal·2009

Same author

WITHDRAWN: Antibiotics for preventing pneumonia in children with measles.

The Cochrane database of systematic reviews·2007

Same author

Outcome-based clinical indicators for intensive care medicine.

Anaesthesia and intensive care·2005

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

子供はどのくらいの頻度で咳をするのか?

関連する概念動画

Corrigendum to "Critical Care Outcome Prediction Equation (COPE) model, version 7" [Crit Care Resusc 27 (4) (2025) 100131].

ANZROD, COPE 4 and PIM 3: caveat emptor.

Heterologous ("nonspecific") and sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms.

Validation of the hospital outcome prediction equation (HOPE) model for monitoring clinical performance.

WITHDRAWN: Antibiotics for preventing pneumonia in children with measles.

Outcome-based clinical indicators for intensive care medicine.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

子供はどのくらいの頻度で咳をするのか?

関連する概念動画

関連記事

Corrigendum to "Critical Care Outcome Prediction Equation (COPE) model, version 7" [Crit Care Resusc 27 (4) (2025) 100131].

ANZROD, COPE 4 and PIM 3: caveat emptor.

Heterologous ("nonspecific") and sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms.

Validation of the hospital outcome prediction equation (HOPE) model for monitoring clinical performance.

WITHDRAWN: Antibiotics for preventing pneumonia in children with measles.

Outcome-based clinical indicators for intensive care medicine.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.